• World News
  • Politics
  • Stock
  • Investing
  • Editor’s Pick
Time And Sales Reporter
Editor's Pick

Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

by admin April 30, 2025
April 30, 2025

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research and development. 

Bourla’s remarks on the company’s first-quarter earnings call came in response to a question about what Pfizer wants to see from tariff negotiations that would push the company to increase investments in the U.S. It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the country — his administration’s bid to boost domestic manufacturing.

“If I know that there will not be tariffs … then there are tremendous investments that can happen in this country, both in R&D and manufacturing,” Bourla said on the call, adding that the company is also hoping for “certainty.”

“In periods of uncertainty, everybody is controlling their cost as we are doing, and then is very frugal with their investment, as we are doing, so that we are prepared for remit. So that’s what I want to see,” Bourla said.

Bourla noted the tax environment, which had previously pushed manufacturing abroad, has “significantly changed now” with the establishment of a global minimum tax of around 15%. He said that shift hasn’t necessarily made the U.S. more attractive, saying “it’s not as good” to invest here without additional incentives or clarity around tariffs.

“Now [Trump] I’m sure — and I know because I talked to him — that he would like to see even a reduction in the current tax regime particularly for locally produced goods,” Bourla said, adding a further decrease would be would be a strong incentive for manufacturing in the U.S.

Unlike other companies grappling with evolving trade policy, Pfizer did not revise its full-year outlook on Tuesday. However, the company noted in its earnings release that the guidance “does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time.”

But on the earnings call on Tuesday, Pfizer executives said the guidance does reflect $150 million in costs from Trump’s existing tariffs.

“Included in our guidance that we didn’t really speak about is there are some tariffs in place today,” Pfizer CFO Dave Denton said on the call.

“We are contemplating that within our guidance range and we continue to again trend to the top end of our guidance range even with those costs to be incurred this year,” he said.

This post appeared first on NBC NEWS

previous post
Tesla: The Breakout to Bolster the Bulls
next post
Crypto Market Recap: Grayscale Debuts New Bitcoin Product, Tether Announces US Expansion

Related Posts

Essence Fest leads a summer of events for...

July 4, 2025

Tariffs and weaker beer demand are weighing on...

July 4, 2025

Microsoft laying off about 9,000 employees in latest...

July 4, 2025

As his feud with Trump reignites, Musk’s business...

July 3, 2025

Apple sues former Vision Pro employee for allegedly...

July 3, 2025

Lululemon sues Costco over selling alleged dupes

July 2, 2025







    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.




    Recent Posts

    • President Trump to honor Iran strike flight team at the White House

      July 5, 2025
    • This July 4th, a family waits: American hostage’s father pleads for son’s freedom from Hamas terrorists

      July 5, 2025
    • Iran regime escalates repression toward ‘North Korea-style model of isolation and control’

      July 5, 2025
    • Quimbaya Gold Closes $4 Million Financing and Expands Executive Team

      July 5, 2025
    • Syntheia Signs Definitive Agreement for Call Center Acquisition

      July 5, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 timeandsalesreporter.com | All Rights Reserved

    Time And Sales Reporter
    • World News
    • Politics
    • Stock
    • Investing
    • Editor’s Pick

    Read alsox

    Should the US Government Privatize the Post Office?

    February 12, 2025

    Why So Much Public Land?

    February 20, 2025

    Five Most Absurd Things about Trump’s “Reciprocal” Tariffs

    April 3, 2025